Key Takeaways LTH, CAH, LMAT and FLS boast high interest coverage ratios, signaling stronger debt-servicing ability.Each stock shows projected EPS and sales growth for the current financial year.All four companies have a Zacks Rank #2 and VGM Scores of A or B, reinforcing their financial strength.An ill-informed investor can easily lose money by betting on a stock solely based on the numbers flashing across a real-time screen. As we move toward 2026, this risk becomes even more pronounced, with the market n ...

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, with the aim of buying high and selling higher, capitalizing on established price movements [1][2]. Company Overview: Cardinal Health (CAH) - Cardinal Health currently holds a Momentum Style Score of A, indicating strong momentum characteristics [3]. - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook based on historical performance metrics [4]. Performance Metrics - Over the past week, CAH shares increased by 2%, outperforming the Zacks Medical - Dental Supplies industry, which rose by 0.57% [6]. - In a longer timeframe, CAH's monthly price change is 29.59%, significantly higher than the industry's 3.41% [6]. - Over the last quarter, CAH shares have risen by 41.56%, and over the past year, they have increased by 73.81%, while the S&P 500 only moved 5.68% and 14.42% respectively [7]. Trading Volume - CAH's average 20-day trading volume is 2,914,504 shares, which serves as a bullish indicator when combined with rising stock prices [8]. Earnings Outlook - In the past two months, 7 earnings estimates for CAH have been revised upwards, with no downward revisions, leading to an increase in the consensus estimate from $9.45 to $9.86 [10]. - For the next fiscal year, 6 estimates have also moved higher, with no downward revisions during the same period [10]. Conclusion - Considering the strong performance metrics and positive earnings outlook, CAH is positioned as a 2 (Buy) stock with a Momentum Score of A, making it a potential candidate for near-term investment [12].

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Cardinal Health (CAH) .Cardinal currently has an average brokerage recomme ...

Core Insights - The American Century U.S. Quality Growth ETF (QGRO) has made significant adjustments to its holdings, reflecting the flexibility of ETF managers in response to market movements [1][3][6] Fund Overview - QGRO was launched in September 2018 and charges 29 basis points for investing in U.S. firms with high growth potential and strong fundamentals [2] - The fund tracks the American Century U.S. Quality Growth Index, which screens for factors like income and quality using metrics such as cash flow and profitability [2] Recent Changes in Holdings - Notable changes in QGRO's portfolio include the dropping of at least two stocks and the addition of two new stocks, along with adjustments to the weights of six existing stocks [3] - Major tech companies such as Alphabet (GOOGL), Meta Platforms (META), and Amazon (AMZN) saw their weights decrease by 1.22%, 1.32%, and 1.74% respectively between November 21 and 24 [3] - Conversely, Amphenol Corporation (APH), Ralph Lauren Corporation (RL), and Expedia Group, Inc. (EXPE) experienced weight increases of 3.53%, 2.1%, and 1.33% respectively [4] Specific Stock Adjustments - The two stocks that were dropped from QGRO included Itron Inc. (ITRI) and Booz Allen Hamilton Holding Corporation (BAH), which had weights of 0.76% and 0.72% respectively before being removed [5] - The largest additions to the fund were Cardinal Health, Inc. (CAH) and HCA Healthcare, Inc. (HCA), with weights of 1.08% and 1.25% respectively [5] Performance Metrics - QGRO has achieved a year-to-date return of 12.4%, focusing on quality and growth-oriented companies [6] - The recent reduction in weight for three major tech stocks may attract investors looking to diversify into other rising companies [6]

Core Viewpoint - Aurinia Pharmaceuticals (AUPH) is currently outperforming its peers in the Medical sector, with a year-to-date return of 74.6% compared to the sector average of 6.3% [4]. Company Performance - Aurinia Pharmaceuticals is ranked 4 in the Zacks Sector Rank among 949 companies in the Medical group [2]. - The Zacks Rank for AUPH is 2 (Buy), indicating a positive earnings outlook [3]. - The Zacks Consensus Estimate for AUPH's full-year earnings has increased by 20.3% in the past quarter, reflecting stronger analyst sentiment [4]. Industry Context - AUPH is part of the Medical - Drugs industry, which consists of 144 companies and is currently ranked 75 in the Zacks Industry Rank [6]. - The average return for stocks in the Medical - Drugs industry this year is 6.1%, indicating that AUPH is performing significantly better [6]. - Another outperforming stock in the Medical sector is Cardinal Health (CAH), which has a year-to-date return of 77.1% and a Zacks Rank of 2 (Buy) [5].

Have you been paying attention to shares of Cardinal Health (CAH) ? Shares have been on the move with the stock up 29.4% over the past month. The stock hit a new 52-week high of $210.33 in the previous session. Cardinal has gained 77.1% since the start of the year compared to the 6.3% move for the Zacks Medical sector and the 13.8% return for the Zacks Medical - Dental Supplies industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, having beaten the Zac ...

Core Insights - Wall Street experienced a rebound on November 21, 2025, with all three major stock indices rising nearly 1% due to investor optimism about a potential rate cut in December following dovish comments from John Williams, president of the Federal Reserve Bank of New York [1] Market Conditions - Despite the rebound, concerns over overvalued AI stocks persist, which could lead to a sell-off in the broader market at any time [2] Investment Strategy - In the current unstable environment, equity investors are advised to avoid high-priced stocks and consider dividend-growth stocks, as these companies typically exhibit strong financial health and provide a defensive hedge against economic uncertainty [3][5] - Dividend-growth stocks are characterized by a history of increasing dividends, which offers downside protection and potential for capital appreciation [5][6] Selected Dividend Growth Stocks - Five dividend growth stocks identified as solid choices include: - **Cardinal Health (CAH)**: Expected fiscal 2026 revenue growth of 16.2%, long-term earnings growth rate of 13.9%, and an annual dividend yield of 0.98% [12][13] - **Barrick Mining (B)**: Projected 2025 revenue growth of 21.5%, long-term earnings growth rate of 38.4%, and an annual dividend yield of 1.64% [14] - **NetEase (NTES)**: Anticipated 2025 revenue growth of 10.4%, long-term earnings growth rate of 9.9%, and an annual dividend yield of 1.70% [15] - **Lam Research (LRCX)**: Expected fiscal 2026 revenue growth of 14.1%, long-term earnings growth rate of 20.3%, and an annual dividend yield of 0.73% [16] - **Enersys (ENS)**: Projected fiscal 2026 revenue growth of 4%, long-term earnings growth rate of 15%, and an annual dividend yield of 0.76% [17] Selection Criteria - The selection of these stocks is based on criteria such as multi-year growth in dividends, sales, earnings per share (EPS), and undervaluation metrics [10][11] - Stocks selected have shown historical growth in dividends, sales, and EPS, indicating strong fundamentals and potential for sustained dividend payments [8][9]

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market engagement and confidence [1] - The Zacks Style Scores are designed to help investors identify stocks with the highest potential to outperform the market in the short term [2] Zacks Style Scores Overview - The Style Scores categorize stocks into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] - Value Score emphasizes finding undervalued stocks based on financial ratios [3] - Growth Score assesses a company's future earnings and financial health to identify sustainable growth opportunities [4] - Momentum Score capitalizes on price trends and earnings outlook changes to identify favorable buying opportunities [5] - VGM Score combines the three styles to highlight stocks with the best overall potential [6] Zacks Rank and Performance - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investment decisions [7] - Stocks rated 1 (Strong Buy) have historically delivered an average annual return of +23.93% since 1988, significantly outperforming the S&P 500 [8] - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal returns [10] Company Spotlight: Cardinal Health (CAH) - Cardinal Health is a major player in healthcare services, serving nearly 90% of U.S. hospitals and managing over 43,000 pharmaceutical shipments daily [12] - The company operates in various segments, including Pharmaceutical & Specialty Solutions and Global Medical Products & Distribution [12] - Cardinal Health holds a Zacks Rank of 2 (Buy) and a VGM Score of A, indicating strong growth potential [13] - The company is projected to achieve year-over-year earnings growth of 18.9% for the current fiscal year, with upward revisions in earnings estimates [13][14]

Group 1: Cardinal Health - Cardinal Health's share prices have surged nearly 74% year to date, with significant gains following a strong quarterly earnings report [3][4] - Fiscal first-quarter 2026 revenue reached $64 billion, a 22% increase from the previous year, exceeding analyst expectations [3][5] - Adjusted earnings per share (EPS) of $2.55 surpassed Wall Street's forecasts, with estimates predicting EPS growth of 19% and 12.6% for the current and next fiscal years, respectively [5] Group 2: Loews - Loews shares have increased by 24% year to date, reflecting a turnaround from weak returns in the 2010s [6][8] - The company, controlled by the Tisch family, focuses on increasing intrinsic value per share and is actively repurchasing shares [9] - Loews owns significant stakes in CNA Financial and has interests in energy pipelines, hotels, and packaging, making it an attractive option for conservative investors seeking steady returns [8][9] Group 3: SanDisk - SanDisk's shares have surged over sixfold since splitting from Western Digital in February, with a 70% increase in the past month [10][11] - The company benefits from a NAND shortage, with robust demand for memory chips driven by artificial intelligence infrastructure [10] - SanDisk has raised NAND flash contract prices by 50%, and the market currently values its shares at a forward price-to-earnings (P/E) ratio of around 19, indicating potential for continued growth [10][12]

Core Viewpoint - A rotation in investor interest is occurring, moving from high-flying tech stocks to undervalued healthcare stocks, driven by strong earnings and emerging uptrends in the healthcare sector [1]. Group 1: Healthcare Sector Overview - The healthcare sector is experiencing a surge, with several stocks showing strong momentum and favorable rankings on Benzinga's Momentum scores [2]. - Investors are increasingly favoring healthcare stocks due to their strong earnings performance and technical indicators suggesting upward trends [1]. Group 2: Cardinal Health Inc. - Cardinal Health (NYSE:CAH) has a market cap of $48 billion and has consistently generated over $50 billion in sales each quarter since Q1 2023, primarily from generic and branded drug sales [4]. - The stock has increased over 70% year-to-date, with a significant 15% jump following a Q3 earnings report that exceeded consensus expectations by more than 16% [6]. Group 3: Guardant Health Inc. - Guardant Health (NASDAQ:GH) specializes in oncology diagnostics and reported a record revenue of $265 million, reflecting over 38% year-over-year growth [9]. - The stock has shown strong momentum, with a significant increase following better-than-expected earnings results [9]. Group 4: Abivax SA - Abivax (NASDAQ:ABVX) focuses on chronic inflammatory diseases and has seen its stock rise nearly 600% in a single session following positive Phase 3 clinical trial results [10]. - The stock has continued to rise, with a 60% increase over the last three months and a consensus Buy rating from analysts [12]. Group 5: Medpace Holdings Inc. - Medpace (NASDAQ:MEDP) provides clinical trial services and has experienced a stock increase of over 75% year-to-date, driven by strong earnings performance [13]. - The company reported Q3 revenue growth of more than 23% year-over-year, exceeding expectations and indicating strong future prospects [15]. Group 6: Elanco Animal Health Inc. - Elanco Animal Health (NYSE:ELAN) develops healthcare products for pets and farm animals, with shares up 76% this year due to solid earnings [16]. - The company raised its full-year guidance following strong sales growth in both its Pet Health and Farm Animal divisions [18]. Group 7: GeneDx Holdings Corp. - GeneDx Holdings (NASDAQ:WGS) specializes in exome and genome testing and has recently turned a profit, with a market cap approaching $4 billion [19]. - The company has raised guidance for total revenue and adjusted gross margins, indicating strong growth potential [19].